Enovis Corporation
Symbol: ENOV (NYSE)
Company Description:
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.
- Today's Open: $31.6
- Today's High: $32.758
- Today's Low: $31.356
- Today's Volume: 781.78K
- Yesterday Close: $31.55
- Yesterday High: $31.6
- Yesterday Low: $30
- Yesterday Volume: 917.53K
- Last Min Volume: 28
- Last Min High: $32.135
- Last Min Low: $32.135
- Last Min VWAP: $32.135
- Name: Enovis Corporation
- Website: https://www.enovis.com
- Listed Date: 2008-05-08
- Location: WILMINGTON, DE
- Market Status: Active
- CIK Number: 0001420800
- SIC Code: 3842
- SIC description: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
- Market Cap: $1.80B
- Round Lot: 100
- Outstanding Shares: 57.16M
- Asset Type: CS
Filing Date | Filing Type | Format |
---|---|---|
2025-08-25 | 4 | View |
2025-08-20 | 4 | View |
2025-08-14 | 4 | View |
2025-08-14 | SCHEDULE 13G/A | View |
2025-08-12 | SCHEDULE 13G/A | View |
2025-08-07 | 4 | View |
2025-08-07 | 4 | View |
2025-08-07 | 4 | View |
2025-08-07 | 10-Q | View |
2025-08-07 | 8-K | View |
2025-07-17 | SCHEDULE 13G/A | View |
2025-07-08 | SCHEDULE 13G/A | View |
2025-07-01 | 4 | View |
2025-06-26 | 11-K | View |
2025-06-03 | 4 | View |
2025-05-30 | SD | View |
2025-05-23 | 4 | View |
2025-05-23 | 4 | View |
2025-05-23 | 4 | View |
2025-05-23 | 4 | View |